An observational study in Anal Carcinoma, Cervical Carcinoma and Human Papillomavirus Infection, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in Costa Rica. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by National Cancer Institute (NCI) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Anus Neoplasms by National Cancer Institute (NCI) — none open to participants now, 5 under way, 2 of them phase 3. Anus Neoplasms · National Cancer Institute (NCI).
Among the 23 studies in Anus Neoplasms by National Cancer Institute (NCI), this one is one of 2 that started in 2009, is one of 2 observational ones, and was the 9th registered.
298 studies on the registry are indexed under Anus Neoplasms; 75 are open to participants now.
Browse Anus Neoplasms studies →None of the 23 studies in Anus Neoplasms by National Cancer Institute (NCI) is open now. The open studies under Anus Neoplasms, anywhere →
Of the 57 Anus Neoplasms studies recruiting now, 46 (81%) set no upper age limit and 7 (12%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 10 · Phase 3 2
First in 1995; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8,670 is above the median of 144 across 75 observational studies indexed under Anus Neoplasms.
Median enrollment 41 across the 20 interventional studies, 4,517 across the 2 observational. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
2 of the studies in Anus Neoplasms by National Cancer Institute (NCI) that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04444921Phase 3National Cancer Institute (NCI)EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients | 2027-03-31 |
| NCT00867464National Cancer Institute (NCI)Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls | 2026-12-23 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Anus Neoplasms by National Cancer Institute (NCI), from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This research trial studies extended follow up of young women in Costa Rica who received vaccine for human papillomavirus types 16 and 18 and unvaccinated controls. Collecting information from young women in Costa Rica who have received vaccine for human papillomavirus types 16 and 18 and a new group of unvaccinated controls enrolled for the follow-up period, may help doctors learn more about the risks and benefits of prophylactic human papillomavirus vaccine.
PRIMARY OBJECTIVES:
I. To evaluate the 10-year global impact of human papillomavirus (HPV)-16/18 vaccination of young adult women.
II. To evaluate determinants of the immune response to HPV and the vaccine, and markers of long-term protection.
III. To evaluate the natural history of HPV and cervical disease in vaccinated and unvaccinated populations.
OUTLINE:
Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.
Young women in Costa Rica who received vaccination against human papillomavirus types 16 and 18 and unvaccinated controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.
Other: Cytology Specimen Collection Procedure · Other: Laboratory Biomarker Analysis · Other: Long-term Follow-up · Other: Questionnaire Administration
Correlative studies
Also known as: Cytologic Sampling
Correlative studies
Undergo extended follow-up
Also known as: long term follow-up (clinical study), long-term follow-up (research), LTFU
Ancillary studies
Cumulative rate of cervical intraepithelial neoplasia 3 (CIN3)
Both absolute rate differences and percent reduction in rates will be evaluated.
Time frame: At 10 years
Level of immune response markers as prediction of long-term success of HPV vaccine
For efficiency, a nested case-control approach is envisioned to evaluate this question. We propose to compare women who become infected against a subset of those who do not (non-failures) with respect to immune response markers of interest.
Time frame: Up to 10 years
Increase in the rate of cervical lesions associated with other carcinogenic HPV types that the vaccine does not protect against from prevention of HPV-16/18 associated cervical lesions through vaccination
The 10-year cumulative rate of incident CIN2+ associated with HPV types other than HPV-16/18 and closely related HPV types in the alpha-7/9 species for which evidence of vaccine cross-protection is demonstrated will be compared between vaccinated and unvaccinated women.
Time frame: Up to 10 years
Started Mar 2009 (actual). Primary completion is estimated for Dec 2026, 212 months after the start.
Of 36 observational studies under Anus Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 137. This study's planned 212 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Institute (NCI) →